Charles River Laboratories International, Inc. EPS Estimates for FY2023 Decreased by Zacks Research

Trending News 🌥️

CRL Stock Intrinsic Value – Charles River Laboratories($NYSE:CRL) International, Inc. is a leading provider of drug discovery, development and manufacturing services. This decrease is due to lower revenue estimates and higher costs.

Despite the decrease in EPS estimates, CRL remains a strong company with a solid reputation. CRL has a long history of providing quality services and products to its clients, and is expected to continue to do so in the future.

Earnings

In the latest earning report for the FY2022 Q2, CHARLES RIVER LABORATORIES INTERNATIONAL earned a total revenue of 3688.0M USD and a net income of 443.3M USD. This is compared to the previous year where there was a 4.2% increase in total revenue and a 13.4% increase in net income. The total revenue for CHARLES RIVER LABORATORIES INTERNATIONAL has reached from 2923.9M USD to 3688.0M USD in the last 3 years.

Price History

The stock closed the day at $184.8 per share.

VI Analysis – CRL Stock Intrinsic Value

Charles River Laboratories International is a global provider of drug discovery, development and manufacturing services. The company’s fundamentals reflect its long term potential, making it an attractive investment proposition. The fair value of CRL shares is around $290.3, calculated by VI Line. This indicates that the stock is currently undervalued by 36%.

Summary

This decrease in EPS estimates follows the stock price movement down on the same day. Investors may want to consider CRL as a potential investment. The company’s strong research capabilities and broad range of services could make it a valuable partner for drug development companies. CRL’s stock price may be down in the short-term, but the company’s long-term prospects appear to be strong.